Abstract
Inflammation is implicated in the development and severity of the coronavirus disease 2019 (COVID-19), as well as in the pathophysiology of diabetes. Diabetes, especially when uncontrolled, is also recognized as an important risk factor for COVID-19 morbidity and mortality. Furthermore, certain inflammatory markers [i.e. C-reactive protein (CRP), interleukin-6 (IL-6) and ferritin] were reported as strong predictors of worse outcomes in COVID-19 positive patients. The same biomarkers have been associated with poor glycemic control. Therefore, achieving euglycemia in patients with diabetes is even more important in the era of the COVID-19 pandemic.
Based on the above, it is clinically interesting to elucidate whether antidiabetic drugs may reduce inflammation, thus possibly minimizing the risk for COVID-19 development and severity. The present narrative review discusses the potential anti-inflammatory properties of certain antidiabetic drugs (i.e. metformin, pioglitazone, sitagliptin, linagliptin, vildagliptin, alogliptin, saxagliptin, liraglutide, dulaglutide, exenatide, lixisenatide, semaglutide, empagliflozin, dapagliflozin, canagliflozin), with a focus on CRP, IL-6 and ferritin.
【저자키워드】 C-reactive protein, ferritin, interleukin 6, metformin, pioglitazone, Dipeptidyl peptidase 4 inhibitors, Glucagon-like peptide-1 receptor agonists, Sodium-glucose co-transporter-2 inhibitors, 【초록키워드】 COVID-19, coronavirus disease, Inflammation, Biomarker, IL-6, COVID-19 pandemic, severity, interleukin-6, risk, CRP, diabetes, outcome, risk factor, pathophysiology, morbidity and mortality, Inflammatory marker, predictor, glycemic control, antidiabetic drug, COVID-19 positive patients, reported, clinically, reduce, implicated, anti-inflammatory property, patients with diabete, 【제목키워드】 COVID-19,